Medplus Health Services has disclosed that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at three of its stores in Karnataka and Maharashtra. The suspensions, ordered under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945, are expected to result in a potential revenue loss of approximately Rs 6.89 lacs.

Details of the Suspensions

The company provided a breakdown of the suspensions in its regulatory filing:

Regulatory Compliance

The suspension orders were received on August 18, as per the company's disclosure. Medplus Health Services has reported this development in compliance with Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Company Response

Manoj Kumar Srivastava, Company Secretary & Compliance Officer of Medplus Health Services, signed the regulatory filing. The company stated that the information regarding these suspensions would be available on its official website, as well as on the websites of BSE Limited and National Stock Exchange of India Ltd.

While the specific violations or alleged contraventions have not been detailed in the disclosure, the suspensions fall under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. This rule typically pertains to the regulation and control of the manufacture, sale, and distribution of drugs in India.

The impact of these suspensions on Medplus's overall operations remains to be seen, as the company continues to operate numerous other stores across the country.

Medplus Health Services Limited, a prominent player in the Indian healthcare retail sector, has reported a regulatory setback for its subsidiary, Optival Health Solutions Private Limited. The company disclosed that Optival received a four-day suspension order for its drug license at a store located in Quthubullapur, Telangana.

Regulatory Action Details

The suspension order, issued by the Assistant Director of Drugs Control Administration, Quthubullapur, Telangana, cites violations under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The affected store is situated at Modi Splendour, Quthubullapur.

Timeline and Financial Impact

According to the company's filing:

• The suspension order was received on August 14, 2025.
• The regulatory action is expected to result in a potential revenue loss of approximately Rs. 0.80 lakhs for the company.

Compliance and Disclosure

Medplus Health Services Limited promptly reported this development to the stock exchanges on August 15, 2025, in compliance with Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also adhered to the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, in disclosing the details of the matter.

Investor Information

Medplus has assured that the information regarding this suspension will be available on the company's website ( www.medplusindia.com ) as well as on the websites of BSE Limited ( www.bseindia.com ) and National Stock Exchange of India Ltd. ( www.nseindia.com ).

While the immediate financial impact appears limited, this incident highlights the ongoing regulatory challenges faced by pharmaceutical retail chains in India.